Phio Pharmaceuticals Corp.

PHIO

US71880W4024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/05/2024 BST			5-day change	1st Jan Change
0.776 ^USD	+1.44%		+2.12%	+2.11%

05-21	Phio Pharmaceuticals Files $100 Million Mixed Shelf	MT
05-15	Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study	MT

Keith L. Brownlie Not Stands for Re-Election at the 2019 Annual Meeting of Phio Pharmaceuticals Corp

August 30, 2019 at 10:27 pm

Mr. Keith L. Brownlie will not be standing for re-election at the 2019 Annual Meeting of Phio Pharmaceuticals Corp. and his departure is not due to any disagreement or dispute with the Company.

Latest news about Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Files $100 Million Mixed Shelf	05-21	MT
Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study	05-15	MT
Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study	05-15	CI
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	04-22	CI
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	04-16	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	03-21	CI
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research	03-13	CI
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders	03-06	MT
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders	03-06	CI
HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating	02-06	MT
Phio Pharmaceuticals Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas	11-09	CI
Phio Pharmaceuticals Shares Rise After Data Shows Intasyl Compound Enhances Tumor Control	11-03	MT
Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer	11-03	CI
Top Premarket Decliners	12/10/23	MT
Top Midday Gainers	11/10/23	MT
Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894	11/10/23	CI
Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute	21/08/23	CI
Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Phio Pharmaceuticals Completes $4 Million Securities Offering	02/06/23	MT
Phio Pharmaceuticals Corp. announced that it has received $3.999998 million in funding	01/06/23	CI
Phio Pharmaceuticals to Raise $4 Million From Securities Offering; Shares Fall	31/05/23	MT

Chart Phio Pharmaceuticals Corp.

Duration

Period

More charts

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cellsâ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Sector

Biotechnology & Medical Research

Calendar

17/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.776 USD

Average target price

4 USD

Spread / Average Target

+415.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHIO PHARMACEUTICALS CORP.	+2.11%	3.51M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research

Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Biotechnology & Medical Research

Keith L. Brownlie Not Stands for Re-Election at the 2019 Annual Meeting of Phio Pharmaceuticals Corp

Latest news about Phio Pharmaceuticals Corp.

Chart Phio Pharmaceuticals Corp.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research